Nuvation Bio (NYSE:NUVB) Posts Earnings Results, Beats Estimates By $0.04 EPS

Nuvation Bio (NYSE:NUVB) posted its quarterly earnings results on Monday. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.04, FiscalAI reports. Nuvation Bio had a negative return on equity of 57.48% and a negative net margin of 325.31%.The firm had revenue of $83.23 million during the quarter, compared to analyst estimates of $65.73 million.

Here are the key takeaways from Nuvation Bio’s conference call:

• Ibtrozi launch momentum remains strong with ~200 new patient starts for a third consecutive quarter, >600 total since launch, and for the first time >50% of new starts were TKI‑naive (first‑line), signaling a favorable shift in patient mix.
• Updated TRUST data show exceptional durability and CNS activity — a pooled median duration of response of ~50 months in TKI‑naive patients and high intracranial response rates, with low discontinuation rates consistent with trial safety.
• Q1 financials included $83.2M total revenue (including $18.5M in Ibtrozi net U.S. product revenue, +18% Q/Q) plus ~$60M Eisai upfront, and a cash position of ~$533.7 million with an available $50M term loan and an expected ~$30M milestone, which management says supports operations without extra financing.
• Gross‑to‑net (GTN) increased at the start of the year (driven by price changes, 340B/Medicaid dynamics and inflation‑related adjustments), pressuring net revenue, though management expects GTN to stabilize over time.
• Safusidenib program advancing: ongoing Phase III SIGMA in IDH1 mutant glioma, acquisition of Japan rights from Daiichi Sankyo, and long‑term Phase II durability signals (e.g., 12/27 patients on treatment >5 years) supporting broad market potential.

Nuvation Bio Price Performance

NYSE:NUVB opened at $4.45 on Tuesday. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -7.42 and a beta of 1.51. Nuvation Bio has a 52-week low of $1.57 and a 52-week high of $9.75. The stock has a fifty day moving average of $4.72 and a 200 day moving average of $5.92. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.81 and a current ratio of 6.95.

Wall Street Analyst Weigh In

NUVB has been the subject of a number of analyst reports. Royal Bank Of Canada raised their price target on Nuvation Bio from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research note on Tuesday, April 21st. Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Nuvation Bio in a research note on Thursday, April 16th. HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Nuvation Bio in a research note on Tuesday. Finally, UBS Group dropped their price objective on Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating for the company in a research note on Tuesday, March 3rd. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Nuvation Bio presently has an average rating of “Moderate Buy” and a consensus target price of $11.63.

Insider Buying and Selling at Nuvation Bio

In related news, insider Dongfang Liu sold 50,000 shares of Nuvation Bio stock in a transaction on Friday, April 17th. The stock was sold at an average price of $5.02, for a total transaction of $251,000.00. Following the completion of the sale, the insider owned 18,000 shares of the company’s stock, valued at approximately $90,360. This trade represents a 73.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kerry Wentworth sold 36,750 shares of Nuvation Bio stock in a transaction on Friday, April 17th. The shares were sold at an average price of $5.01, for a total value of $184,117.50. Following the sale, the insider directly owned 53,000 shares of the company’s stock, valued at $265,530. This represents a 40.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 286,750 shares of company stock valued at $1,339,118 in the last three months. 30.11% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Nuvation Bio

A number of large investors have recently added to or reduced their stakes in the company. HighTower Advisors LLC raised its position in Nuvation Bio by 9.8% during the fourth quarter. HighTower Advisors LLC now owns 22,457 shares of the company’s stock valued at $201,000 after purchasing an additional 2,007 shares in the last quarter. Parallel Advisors LLC raised its position in Nuvation Bio by 51.9% during the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after purchasing an additional 2,597 shares in the last quarter. Russell Investments Group Ltd. raised its position in Nuvation Bio by 17.7% during the fourth quarter. Russell Investments Group Ltd. now owns 24,456 shares of the company’s stock valued at $219,000 after purchasing an additional 3,681 shares in the last quarter. Mackenzie Financial Corp raised its position in Nuvation Bio by 38.8% during the third quarter. Mackenzie Financial Corp now owns 15,746 shares of the company’s stock valued at $58,000 after purchasing an additional 4,400 shares in the last quarter. Finally, Integrated Wealth Concepts LLC raised its position in Nuvation Bio by 21.9% during the third quarter. Integrated Wealth Concepts LLC now owns 24,610 shares of the company’s stock valued at $91,000 after purchasing an additional 4,419 shares in the last quarter. Hedge funds and other institutional investors own 61.67% of the company’s stock.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.